Hennion & Walsh Asset Management Inc. Has $4.19 Million Stock Holdings in Grifols, S.A. $GRFS

Hennion & Walsh Asset Management Inc. grew its stake in Grifols, S.A. (NASDAQ:GRFS) by 13.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 592,173 shares of the biotechnology company’s stock after acquiring an additional 72,037 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Grifols were worth $4,193,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brandes Investment Partners LP raised its holdings in Grifols by 6.3% during the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after acquiring an additional 1,838,727 shares in the last quarter. Permian Investment Partners LP grew its stake in Grifols by 4.2% in the fourth quarter. Permian Investment Partners LP now owns 18,190,262 shares of the biotechnology company’s stock valued at $170,079,000 after purchasing an additional 737,941 shares in the last quarter. Millennium Management LLC grew its stake in Grifols by 2.7% in the fourth quarter. Millennium Management LLC now owns 7,122,155 shares of the biotechnology company’s stock valued at $66,592,000 after purchasing an additional 184,874 shares in the last quarter. Bank of Montreal Can increased its position in shares of Grifols by 45.8% during the 4th quarter. Bank of Montreal Can now owns 4,394,750 shares of the biotechnology company’s stock worth $41,091,000 after purchasing an additional 1,381,027 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Grifols by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after purchasing an additional 80,507 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings downgraded shares of Grifols from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, July 31st. Finally, Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Grifols currently has a consensus rating of “Reduce” and an average price target of $10.00.

Grifols Stock Performance

Shares of NASDAQ GRFS opened at $8.05 on Tuesday. The company has a current ratio of 2.37, a quick ratio of 0.81 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $5.48 billion, a P/E ratio of 42.37, a P/E/G ratio of 0.29 and a beta of 0.67. Grifols, S.A. has a 12 month low of $6.96 and a 12 month high of $10.84. The stock has a 50 day moving average of $7.51 and a 200-day moving average of $8.13.

Grifols Dividend Announcement

The business also recently disclosed a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were given a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s payout ratio is 115.79%.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.